linjc16/ctgov huggingface dataset:
Use Of Capnography As Surrogate Measure Of PC02 In Medical Intensive Care Unit (ICU) Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the use of Capnography (Continuous recording of the carbon dioxide content of expired air)as an alternative test to measure PC02 levels in patients with asthma, chronic obstructive pulmonary (COPD,interstitial lung disease(ILD)or coronary disease who are at risk of intubation.

Detailed Description
-----------------
This is a prospective study to evaluate the usefulness of capnography as a non-invasive, accurate method of measuring of PC02 levels in medical intensive care unit patients with asthma, COPD, ILD, or coronary disease who are at risk of intubation.

Official Title
-----------------
Use Of Capnography As Surrogate Measure Of PC02 In Medical ICU Patients

Conditions
-----------------
Asthma, Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease

Intervention / Treatment
-----------------
* Procedure: Capnography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Medical Intensive Care Patients Not intubated Age 18 or older History of any one of the following: asthma, COPD, ILD, or coronary disease Exclusion Criteria: Sepsis Life expectancy less than 1 month Requiring BIPAP

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Medical Intensive care unit patients with asthma, COPD, ILD or coronary disease who are at risk of intubation | Procedure: Capnography<br>* A technique for monitoring the concentration or partial pressure of CO2 levels in respiratory gases<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PCO2 level |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to intubation |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PC02, Respiratory Rate, Arterial blood gas, Intubation, Capnography
Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking

Study Overview
=================
Brief Summary
-----------------
dry eye disease after corneal collagen cross linking affect ocular function leading to reduced vision, photophobia, glare, halos, and foreign body sensation.

Detailed Description
-----------------
first group of patients were treated with 0.5 % xiidra twice daily and artificial tears for 6 months.Second group treated with artificial tears for 6 months. the treatment starts after corneal collagen cross linking in both groups ,Baseline and post-treatment full ophthalmic examination was done.

Official Title
-----------------
Efficacy of Xiidra in the Management Dry Eye Disease After Corneal Collagen Cross Linking

Conditions
-----------------
Corneal Disease

Intervention / Treatment
-----------------
* Drug: Xiidra 5% Ophthalmic Solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: corneal collagen cross linking Exclusion Criteria: systemic or ocular diseases ,previous ocular surgery, corneal pathology and contact lens wearers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: xiidra group<br>patients are treated with 0.5 % xiidra twice daily and artificial tears for 6 months after corneal collagen cross linking | Drug: Xiidra 5% Ophthalmic Solution<br>* lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking<br>* Other names: lifitegrast;|
| No Intervention: control group<br>patient are treated with artificial tears for 6 months after corneal collagen cross linking in both groups | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Break up Time | fluorescein sodium stripes will be used for measurement of Break up Time in seconds at baseline and during the study | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dry eye, cross linking, xiidra
Study of the Inflammatory Microenvironment in Atypical Meningiomas

Study Overview
=================
Brief Summary
-----------------
Atypical meningiomas represent 15% of meningiomas. They present a high rate of recurrence, and therapeutic strategies are limited. There is a need for novel treatment strategies, such as immuotherapy. This is a retrospective study including 84 patients with primary diagnosis of atypical meningiomas. The presence of T cells (CD4, CD8, Treg and memory T cells) and mature dendritic cells will be quantified on whole tissue sections stained by immunohistochemistry (CD4, CD8, FOXP3, CD45RO and CD208). This could allow us to identify novel biomarkers for survival, and facilitate the selection of patients who may benefit from immunotherapeutic modalities.

Official Title
-----------------
Prognostic Impact of the Inflammatory Microenvironment in Atypical Meningiomas

Conditions
-----------------
Atypical Meningioma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: primary diagnosis of atypical meningioma surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival |  | 2-21 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 2-21 years |
Identification of Undiagnosed Lysosomal Acid Lipase Deficiency

Study Overview
=================
Brief Summary
-----------------
Partners HealthCare maintains a Patient Data Registry (PDR) with information from all patient encounters at Partners HealthCare facilities. We intend to utilize the PDR to identify groups of patient who are of high clinical suspicion for undiagnosed lysosomal acid lipase deficiency. A group of potential participants will be identified through the PDR. Detailed records will be requested to further narrow to ideal participants based upon previously existing diagnoses and symptoms. Participants will be invited to partake in the study via a letter from their Partners care provider with supporting study details. Study participants will be evaluated in a one-time visit. A complete family and medical history will be collected. A physical exam will be performed, and up to 20cc of blood will be drawn. All participants will be notified of their disease status via letter and phone call from the study staff. If the study participant is diagnosed with LALD through this evaluation, proper follow-up recommendations and referrals will be provided. Our intent is to determine if existing patient data can successfully be utilized to aid in the identification of patients with rare genetic disease.

Official Title
-----------------
Identification of Undiagnosed Lysosomal Acid Lipase Deficiency

Conditions
-----------------
Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease

Intervention / Treatment
-----------------
* Other: enzyme analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals must have records available in the Partners HealthCare Patient Data Registry Exclusion Criteria: Individuals must not have a diagnosis of Lysosomal Acid Lipase Deficiency
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Enzyme analysis<br>Patients invited for evaluation will undergo lysosomal acid lipase enzyme analysis | Other: enzyme analysis<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patients with previously undiagnosed GD identified Time Frame: up to 2 years Description: Safety Issue?: No number of patients with previously undiagnosed LALD identified |  | up to 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Lysosomal Storage Disorder, Metabolic Disease, Recessive Inheritance
Treatment of Adolescent Suicide Attempters (TASA)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.

Detailed Description
-----------------
Suicide is the third leading cause of death in adolescents and is a major public health problem. Depression is the most common diagnosis for adolescent suicide attempts. Little is known about what treatment is best for these adolescents since they are usually excluded from participation in research studies. Participants in this study will be randomly assigned to receive carefully monitored antidepressant medication with routine support and management, cognitive behavioral therapy (CBT), or a combination of antidepressant medication plus CBT.

Conditions
-----------------
Depression, Suicide, Attempted

Intervention / Treatment
-----------------
* Drug: fluoxetine
* Drug: sertraline
* Drug: citalopram
* Drug: escitalopram
* Drug: bupropion
* Drug: mirtazapine
* Drug: venlafaxine
* Drug: lithium
* Behavioral: Cognitive Behavioral Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least one suicide attempt or interrupted attempt within the past 45 days Continuously reside with a primary caretaker (parent, legal guardian, foster parent) for at least 6 months that can provide legal consent

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: fluoxetine|nan|
|Drug: sertraline|nan|
|Drug: citalopram|nan|
|Drug: escitalopram|nan|
|Drug: bupropion|nan|
|Drug: mirtazapine|nan|
|Drug: venlafaxine|nan|
|Drug: lithium|nan|
|Behavioral: Cognitive Behavioral Therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dysthymic Disorder, Adolescent
Non Pharmacological Management of Behavioural Symptoms in Nursing Home

Study Overview
=================
Brief Summary
-----------------
Background: Behavioural and psychological symptoms of dementia (BPSD) are often reported in institutions for the elderly. Objective: To evaluate the effectiveness of a staff education intervention to manage BPSD in older people with a diagnosis of dementia.

Detailed Description
-----------------
Background: Behavioural and psychological symptoms of dementia (BPSD) are often reported in institutions for the elderly. Objective: To evaluate the effectiveness of a staff education intervention to manage BPSD in older people with a diagnosis of dementia. Methods: The trial was conducted in 16 nursing homes; 306 patients with a diagnosis of dementia and presenting BPSD were selected. Nursing homes were randomly allocated to an intervention group or a control group. An eight-week staff education and training programme was conducted in the nursing homes in the intervention group. The main outcome measures were the Cohen-Mansfield Agitation Inventory (CMAI) and an observation scale score. Assessments were done at baseline (W0), at the end of the 'intervention' period (W8) and 12 weeks after (W20).

Official Title
-----------------
Not Pharmacologic Treatment Has Illness of Alzheimer and Pathologies Related. Application in Disturbances of Behaviour in EHPAD

Conditions
-----------------
ALZHEIMER Disease

Intervention / Treatment
-----------------
* Other: Training and valuation of the treating personnel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Alzheimer disease Exclusion Criteria: Not alzheimer disease

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: 1- The reference group<br>one will take care of the patient in a habitual way: no consultation additional, step of exam on top of that... | |
| Other: 2- The intervention group<br>Training and valuation of the treating personnel | Other: Training and valuation of the treating personnel<br>* Training and valuation of the treating personnel<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes at the behavioural assessment (CMAI, OS, NPI) after 8 weeks of intervention |  | 8 weeks after intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes at the behavioural assessment (CMAI, OS, NPI) 16 weeks after the end of the intervention |  | 16 weeks after intervention |
To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 300 mg ER Tablets under fasting conditions.

Official Title
-----------------
A Relative Bioavailability Study of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions

Conditions
-----------------
Depression

Intervention / Treatment
-----------------
* Drug: Bupropion HCI 300 mg Extended-Release Tablets EON
* Drug: WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: Positive test results for HIV or hepatitis B orc. Treatment for drug or alcohol dependence.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 58 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Bupropion HCl 300mg Extended Release Tablet | Drug: Bupropion HCI 300 mg Extended-Release Tablets EON<br> <br> |
| Active Comparator: 2<br>WELLBUTRIN XL 300mg Tablets | Drug: WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence according to US FDA timelines |  | 17 days |
Observation of the Gait Cycle in Patients With Hemiplegia in Order to Improve the Triggering of Functional Electrical Stimulation

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is the estimation and comparison of the dephasing between the switch heel and the inertial placed on the paretic foot compared to the events of the gait cycle determined by a Gaitrite system (beginning and end of the swing phase) in conditions without stimulation.

Official Title
-----------------
Observation of the Gait Cycle in Patients With Hemiplegia in Order to Improve the Triggering of Functional Electrical Stimulation

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Other: Gait analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient has had a first ischemic or hemorragic stroke (supratentorial) within the last 6 months for the recent stroke group, or more than a year ago for the old stroke group the patient can walk 10 m without human help, with or without a cane, and a deficit of the foot levator requiring the use of technical assistance to remedy this or involving walking problems electrostimulated contraction of the anterior tibialis is possible patient has been informed and has signed the consent form Exclusion Criteria: cognitive disorder making participation in the study difficult fixed plantar flexion, knee extended below 0° patient refuses to sign consent patient is not covered by a social security system patient is under any kind of guardianship

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Recent stroke group<br>These patients have hemiplegia following a stroke within the last 6 months | Other: Gait analysis<br>* A Gaitrite system, a goniometer, and EMG are used to record data while the patient walks 10 meters.<br>|
| Old stroke group<br>The patients have hemiplegia following a stroke that took place at least a year ago | Other: Gait analysis<br>* A Gaitrite system, a goniometer, and EMG are used to record data while the patient walks 10 meters.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Timing of heel strike (s) | The goal is to use the data generated by this observational study to predict the timing of the heel strike when a patient walks. | 10 seconds |
Effects of a Positive Slope Treadmill Training in Individuals After Stroke. (Hemislope)

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to determine if a single session of treadmill training with a positive slope improves the kinematic parameters of the hip, knee and ankle on the paretic lower limb. Secondarily we will quantify the efficiency of a such training on kinetic and functional parameters.

Detailed Description
-----------------
comparison between patients having a single session of treadmill training with slope and those having a single session of treadmill training with no slope

Official Title
-----------------
Evaluation of Biomechanical and Functional Effects of a Positive Slope Treadmill Training in Individuals After Stroke.

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Other: Inclined treadmill training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hemiplegic patient capacity to walk during 20 minutes without technical assistance Exclusion Criteria: patient with bilateral brain lesions previous orthopedic surgery pregnant woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Interventional Model Description: randomised controlled study experimental group : training with slope N=15 control group training with no slope N=15
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: hemiplegic patient<br> | Other: Inclined treadmill training<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| kinematic gait parameters | angles quantification of lower limbs joints | One year | 
| cinetic gait parameters | moments and joints power quantification in the lower limb | one year |